# Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms

> **NCT02846883** · PHASE1 · TERMINATED · sponsor: **VA Office of Research and Development** · enrollment: 28 (actual)

## Conditions studied

- Abdominal Aortic Aneurysm

## Interventions

- **BIOLOGICAL:** 1 million MSCs/kg
- **BIOLOGICAL:** 3 million MSCs/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02846883
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-05
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Early Termination as required by VA DSMB due to slow enrollment
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02846883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02846883, "Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02846883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*